drugset / Trial / NCT06561308
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Phase 2
Recruiting
39 enrolled
Women's Hospital School Of Medicine Zhejiang University
Anhui Provincial Cancer Hospital · collabFirst Affiliated Hospital of Wenzhou Medical University · collabHenan Provincial People's Hospital · collabHunan Cancer Hospital · collabNingbo No. 1 Hospital · collabQilu Hospital of Shandong University · collabSichuan Cancer Hospital and Research Institute · collabThe First Affiliated Hospital of Zhengzhou University · collabTongji Hospital · collabXiangya Hospital of Central South University · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-12-01
- Completion
- 2031-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Carboplatin | Small molecule | 4 unknown | Intravenous |
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |